INVENTIVA (EPA:IVA) The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
Directive transparence : information réglementée
Inventiva reports 2021 Third Quarter Financial Information
Inventiva to host a webcast with Key Opinion Leaders from the AASLD The...
Inventiva announces participation at several conferences in November 2021
Inventiva announces the design of LEGEND, a Phase IIa combination trial...
The New England Journal of Medicine publishes the results of the NATIVE...
Inventiva announces the presentation of five scientific abstracts at the...
Inventiva announces participation at several investor conferences in...
Inventiva announces FDA decision that Fast Track designation granted to...
Inventiva reports 2021 first half financial results and provides a...
Inventiva announces major recruitments to accelerate the development of...
Voir tous les communiqués de INVENTIVA
©Dissemination technology Webdisclosure.com - copyright 2021 SYMEX ECONOMICS all rights reserved